HOME >> MEDICINE >> NEWS
Treatment outcomes of patients with HIV and tuberculosis

In a retrospective study of 700 patients with culture-positive tuberculosis (TB), relapse rates were found to be significantly higher in HIV-infected patients compared to HIV-uninfected patients following a rifamycin-based regimen. Furthermore, TB relapse rates were higher in HIV-infected patients who received intermittent or standard 6-month therapy when compared to those receiving daily or longer treatment.

The results appear in the first issue for June 2007 of the American Journal of Respiratory and Critical Care Medicine, published by the American Thoracic Society.

Payam Nahid, M.D., M.P.H., of the University of California, San Francisco General Hospital, and eight associates reviewed TB cases reported to the San Francisco Tuberculosis Control Program from January 1, 1990, through December 31, 2001.

As a rationale for their study, the researchers state that the optimal duration of TB therapy in HIV-infected subjects is unknown and may differ from HIV-uninfected individuals.

According to the authors, the current preferred regimen for treating drug-susceptible TB in HIV-uninfected patients is a 6-month, rifamycine-based regimen that includes pyrazinamide during the first two months. Current guidelines for the treatment of TB do not distinguish between those infected with the virus that causes AIDS and those who are uninfected in terms of the optimum length of treatment when using rifamycine.

"Standard 6-month therapy may be insufficient to prevent relapse in patients with HIV," said Dr. Nahid.

The TB relapse rate for HIV-infected patients was found to be 6.6 percent versus 0.8 percent in uninfected/unknown patients. This finding was in contrast to other studies that did not find any significant difference between HIV-infected and HIV-uninfected/unknown patients. However, this finding was corroborated by a similar study that also used molecular genotyping as a relapse indicator.

HIV-i
'"/>

Contact: Brian Kell
bkell@thoracic.org
212-315-6442
American Thoracic Society
1-Jun-2007


Page: 1 2

Related medicine news :

1. Treatment for early prostate cancer associated with type of specialist seen
2. Treatment of kidney condition requires an individualized approach
3. Treatment of in-hospital cardiac patients is focus of Jefferson University presentations
4. Treatment for homeless youth pays off in long run, study finds
5. Treatment discovered for deadly childhood disease
6. Treatment developed for patients with medically unexplained symptoms
7. Treatment drug may cause jawbone to die
8. Treatment for anorexia nervosa appears to have improved outcome
9. Treatment reduces gastric ulcers in at-risk patients using long-term NSAIDS
10. North Central Cancer Treatment Group finding ways to make treatment easier
11. Treatment of severe coronary artery disease with drug-eluting stents a viable alternative to CABG

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/8/2019)... ... 08, 2019 , ... Intelligent.com, a trusted resource for online ... Programs for 2020. The comprehensive research guide is based on an assessment of ... on curriculum quality, graduation rate, reputation, and post-graduate employment. , The 2020 ...
(Date:12/6/2019)... ... December 06, 2019 , ... Connecticut is home ... excellence in patient care. On December 12th, Hartford Business Journal will recognize eight ... Care Heroes Awards at the Hartford Marriott. , “We are fortunate to have ...
(Date:12/6/2019)... ... December 06, 2019 , ... ... HIPAA compliance solution for the Wyoming Medical Society. Compliancy Group is dedicated to ... entities have an obligation to adhere to the standards set forth by the ...
(Date:12/5/2019)... ... December 05, 2019 , ... A cohort of ... technology to help their patients more easily detect ruptured silicone gel implants. Dr. ... study and reporting on his experience. While the FDA currently recommends regular MRI ...
(Date:12/5/2019)... , ... December 05, 2019 , ... ... milestones ranging from launching exceptional products that help people embrace, achieve, and maintain ... , “We’ve never been more committed to our mission of impacting world health, ...
Breaking Medicine News(10 mins):
(Date:12/6/2019)... (PRWEB) , ... December 06, 2019 , ... ... on development of treatments for psychiatric and neurodegenerative disorders, announced today that the ... application for NBTX-001 Inhaler, allowing the Company to initiate its Phase 2b trial ...
(Date:12/6/2019)... GILBERT, Ariz. (PRWEB) , ... December 06, 2019 ... ... the Industry Nutrition Forum in Philadelphia to share information and ideas about working ... percentage of the population. , “It’s vital that we develop a healthy and ...
(Date:12/6/2019)... , ... December 06, 2019 , ... ... agreement with Forbidden Fruit Garden Supply LLC (a division of Horticultural Holdings LLC) ... clientele of professional growers. , FFGS is a team of disciplined and ...
Breaking Medicine Technology:
Cached News: